CEBP Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Begleiter, A.
Right arrow Articles by Bird, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Begleiter, A.
Right arrow Articles by Bird, R. P.
Cancer Epidemiology Biomarkers & Prevention Vol. 12, 566-572, June 2003
© 2003 American Association for Cancer Research

Induction of NAD(P)H Quinone

Oxidoreductase1 Inhibits Carcinogen-induced Aberrant Crypt Foci in Colons of Sprague-Dawley Rats1

Asher Begleiter2, Kosala Sivananthan, Thomas J. Curphey and Ranjana P. Bird

Manitoba Institute of Cell Biology, CancerCare Manitoba, Winnipeg, Manitoba R3E 0V9 Canada [A. B., K. S.]; Departments of Internal Medicine [A. B., K. S.], Pharmacology and Therapeutics [A. B.], and Human Nutritional Sciences [R. P. B.], University of Manitoba, Winnipeg, Manitoba R3E 0V9 Canada; and Department of Pathology, Dartmouth College, Hanover, New Hampshire 03755 [T. J. C.]

Phase II detoxifying enzymes like NAD(P)H (quinone acceptor)oxidoreductase1 (NQO1), glutathione S-transferases (GST), and UDP-glucuronyltransferases (UGT) may play an important role in preventing carcinogen-induced cancers. Inducers of these enzymes have been shown to inhibit carcinogen-induced colon tumors in rat and mouse models. However, it has not been clearly demonstrated that NQO1 contributes to this effect. We examined the effect of NQO1 inducers on colon carcinogenesis using an aberrant crypt foci (ACF) rat model. Sprague-Dawley rats were fed control diet or diet containing 400 ppm dimethyl fumarate or 200 ppm oltipraz for 7 days, and Phase II enzymes in rat colon and liver were measured. Dimethyl fumarate significantly increased NQO1 and GST activities in colon and liver but did not increase UGT activities in these tissues. In contrast, oltipraz significantly increased NQO1 activities in colon and liver and produced a small increase in GST activity in the liver but did not increase GST activity in the colon or UGT activities in the liver or colon. Sprague Dawley rats were fed control diet or diet containing 200 ppm oltipraz and then treated with the carcinogens azoxymethane or methyl nitrosourea. Both carcinogens produced ACF in all of the rat colons, but rats fed oltipraz diet had significantly fewer ACF than those fed control diet. This protective effect was reversed in rats treated with the NQO1 inhibitor, dicoumarol. However, treatment with oltipraz did not alter the distribution of crypt multiplicities in the ACF. These studies demonstrated that induction of NQO1 plays a significant role in inhibiting initiation of carcinogen-induced ACF in Sprague-Dawley rats. This provides the first direct evidence that NQO1 may play a role in preventing colon cancer. The study also found that oltipraz added to the diet of Sprague-Dawley rats selectively increased NQO1 activity in colon mucosa with no increase in GST and UGT activities in these tissues. Thus, this model will be useful for further investigating the role of NQO1 in prevention of colon cancer.




This article has been cited by other articles:


Home page
Toxicol PatholHome page
L. M. Aleksunes and J. E. Manautou
Invited Review: Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease
Toxicol Pathol, June 1, 2007; 35(4): 459 - 473.
[Abstract] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Begleiter, D. Hewitt, A. W. Maksymiuk, D. A. Ross, and R. P. Bird
A NAD(P)H:Quinone Oxidoreductase 1 Polymorphism Is a Risk Factor for Human Colon Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2422 - 2426.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. Piton, E. Le Ferrec, S. Langouet, C. Rauch, E. Petit, F. Le Goff, A. Guillouzo, and F. Morel
Oltipraz regulates different categories of genes relevant to chemoprevention in human hepatocytes
Carcinogenesis, February 1, 2005; 26(2): 343 - 351.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. Munday and C. M. Munday
Induction of phase II enzymes by 3H-1,2-dithiole-3-thione: dose-response study in rats
Carcinogenesis, September 1, 2004; 25(9): 1721 - 1725.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Zhang and G. B. Gordon
A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway
Mol. Cancer Ther., July 1, 2004; 3(7): 885 - 893.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2003 by the American Association for Cancer Research.